• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异源初免-加强：突破 COVID-19 候选疫苗保护性免疫应答瓶颈。

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.

机构信息

National Institutes for Food and Drug Control, Beijing, People's Republic of China.

出版信息

Emerg Microbes Infect. 2021 Dec;10(1):629-637. doi: 10.1080/22221751.2021.1902245.

DOI:10.1080/22221751.2021.1902245
PMID:33691606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8009122/
Abstract

COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.

摘要

不同平台研发的 COVID-19 疫苗在功效、保护持续时间和副作用方面存在差异。为了最大程度地发挥疫苗接种的效益，我们探索了使用异源初免-加强策略的效用，该策略测试了在中国处于临床试验阶段的四种主要 COVID-19 候选疫苗的不同组合在小鼠模型中的效果。我们的结果表明，腺病毒载体疫苗序贯免疫后接种灭活/重组亚单位/mRNA 疫苗，可特异性提高中和抗体水平，并促进抗体反应向主要为中和抗体的方向转变。此外，腺病毒载体疫苗的异源初免-加强方案也改善了 Th1 偏向的 T 细胞反应。我们的研究结果为开发和应用 COVID-19 疫苗控制 SARS-CoV-2 大流行提供了新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/e98bcd19c0a6/TEMI_A_1902245_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/03cc3cf6bd8b/TEMI_A_1902245_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/e994eeffd96f/TEMI_A_1902245_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/3a15d0fa2c06/TEMI_A_1902245_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/e98bcd19c0a6/TEMI_A_1902245_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/03cc3cf6bd8b/TEMI_A_1902245_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/e994eeffd96f/TEMI_A_1902245_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/3a15d0fa2c06/TEMI_A_1902245_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77cc/8009122/e98bcd19c0a6/TEMI_A_1902245_F0004_OC.jpg

相似文献

1
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.异源初免-加强：突破 COVID-19 候选疫苗保护性免疫应答瓶颈。
Emerg Microbes Infect. 2021 Dec;10(1):629-637. doi: 10.1080/22221751.2021.1902245.
2
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.用异源疫苗加强免疫可有效提高灭活 SARS-CoV-2 疫苗的保护免疫应答。
Emerg Microbes Infect. 2021 Dec;10(1):1598-1608. doi: 10.1080/22221751.2021.1957401.
3
Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.新型腺病毒载体 COVID-19 疫苗候选物对小鼠和食蟹猕猴的加强免疫接种。
Emerg Microbes Infect. 2021 Dec;10(1):1002-1015. doi: 10.1080/22221751.2021.1931466.
4
Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.鼻腔内给予未佐剂的 SARS-CoV-2 刺突抗原可增强小鼠和仓鼠中经蛋白亚单位疫苗初免后的抗原特异性免疫应答。
Eur J Immunol. 2024 Jun;54(6):e2350620. doi: 10.1002/eji.202350620. Epub 2024 Apr 1.
5
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.mRNA疫苗CV07050101低剂量初免-加强免疫接种在非人灵长类动物中的免疫原性
Viruses. 2021 Aug 19;13(8):1645. doi: 10.3390/v13081645.
6
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.恒河猴腺病毒 COVID-19 疫苗对小鼠适应 SARS-CoV-2 的保护效力。
J Virol. 2021 Nov 9;95(23):e0097421. doi: 10.1128/JVI.00974-21. Epub 2021 Sep 15.
7
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.异源疫苗接种方案，使用自我扩增 RNA 和腺病毒 COVID 疫苗，可在小鼠中诱导强烈的免疫反应。
Nat Commun. 2021 May 17;12(1):2893. doi: 10.1038/s41467-021-23173-1.
8
Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.用腺病毒载体和蛋白纳米颗粒进行异源初免-加强免疫接种可诱导针对中东呼吸综合征冠状病毒的 Th1 和 Th2 反应。
Vaccine. 2018 Jun 7;36(24):3468-3476. doi: 10.1016/j.vaccine.2018.04.082. Epub 2018 May 5.
9
Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus.异源初免-加强免疫：抗坦布苏病毒的重要候选免疫策略。
Virol J. 2020 May 12;17(1):67. doi: 10.1186/s12985-020-01334-w.
10
Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2.HC009 mRNA 疫苗对 SARS-CoV-2 的免疫原性和保护效力。
Front Immunol. 2024 Jul 26;15:1416375. doi: 10.3389/fimmu.2024.1416375. eCollection 2024.

引用本文的文献

1
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.莫桑比克队列中接种1剂或2剂BBIBP-CorV疫苗后的混合免疫
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S57-S65. doi: 10.1093/cid/ciaf095.
2
Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations.戊型肝炎病毒针对特殊人群的疫苗接种策略及研究空白
Vaccines (Basel). 2025 Jun 9;13(6):621. doi: 10.3390/vaccines13060621.
3
Recent advances on coxsackievirus A6 vaccine research.柯萨奇病毒A6疫苗研究的最新进展。

本文引用的文献

1
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
2
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
3
Front Immunol. 2025 Jun 6;16:1603028. doi: 10.3389/fimmu.2025.1603028. eCollection 2025.
4
Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants.异源初免-加强免疫接种可驱动基质激活和针对新冠病毒变异株的适应性免疫。
Front Immunol. 2025 May 28;16:1597417. doi: 10.3389/fimmu.2025.1597417. eCollection 2025.
5
Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation.mRNA加强疫苗接种后对SARS-CoV-2产生有效的细胞免疫和中和免疫与浆细胞样树突状细胞（pDC）和B细胞活化有关。
Front Immunol. 2025 May 12;16:1580448. doi: 10.3389/fimmu.2025.1580448. eCollection 2025.
6
Decade-Long Sustained Cellular Immunity Induced by Sequential and Repeated Vaccination with Four Heterologous HIV Vaccines in Rhesus Macaques.恒河猴中四种异源HIV疫苗序贯及重复接种诱导的长达十年的持续性细胞免疫
Vaccines (Basel). 2025 Mar 21;13(4):338. doi: 10.3390/vaccines13040338.
7
Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19.嵌合受体结合域疫苗设计与序贯免疫增强了针对新冠病毒的广泛中和抗体反应。
Front Immunol. 2025 Mar 27;16:1543212. doi: 10.3389/fimmu.2025.1543212. eCollection 2025.
8
Single-cell transcriptome atlas of peripheral immune features to Omicron breakthrough infection under booster vaccination strategies.加强免疫接种策略下奥密克戎突破性感染外周免疫特征的单细胞转录组图谱
Front Immunol. 2025 Jan 6;15:1460442. doi: 10.3389/fimmu.2024.1460442. eCollection 2024.
9
HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.HIV疫苗接种：探寻变革性突破之路——当前证据综述
Health Sci Rep. 2024 Sep 23;7(9):e70089. doi: 10.1002/hsr2.70089. eCollection 2024 Sep.
10
Sequential Immunization with Vaccines Based on SARS-CoV-2 Virus-like Particles Induces Broadly Neutralizing Antibodies.基于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒样颗粒的疫苗序贯免疫诱导广泛中和抗体。
Vaccines (Basel). 2024 Aug 19;12(8):927. doi: 10.3390/vaccines12080927.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Correlates of protection against SARS-CoV-2 in rhesus macaques.恒河猴中 SARS-CoV-2 保护作用的相关因素。
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
6
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
7
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
8
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
9
Tfh Cells in Health and Immunity: Potential Targets for Systems Biology Approaches to Vaccination.滤泡辅助性 T 细胞在健康与免疫中的作用：系统生物学方法疫苗接种的潜在靶点。
Int J Mol Sci. 2020 Nov 12;21(22):8524. doi: 10.3390/ijms21228524.
10
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.SARS-CoV-2 中和抗体 LY-CoV555 治疗门诊新冠患者的疗效。
N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.